Corcept Therapeutics (CORT) Share-based Compensation (2010 - 2026)

Corcept Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $29.4 million in Q2 2026.

• Quarterly Share-based Compensation rose 287.05% year-over-year to $29.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $77.3 million (up 36.32% YoY) and the FY2025 annual result came in at $84.5 million, up 37.73% from the prior year.
• Share-based Compensation advanced to $29.4 million in Q2 2026 per CORT's latest filing, from $23.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $29.4 million in Q2 2026 and troughed at $800000.0 in Q2 2024.
• A 5-year average of $12.1 million and a median of $11.0 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation plunged 72.73% in 2023, then soared 850.0% in 2025.
• Over 5 years, Share-based Compensation stood at $10.5 million in 2022, then rose by 24.18% to $13.1 million in 2023, then grew by 28.56% to $16.8 million in 2024, then increased by 23.65% to $20.8 million in 2025, then surged by 41.64% to $29.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $29.4 million, $23.0 million, and $20.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.